µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis

Exclusion Criteria

• •Previous treatment with pamidronate, ibandronate, of more than 2 doses in 2 years and of zoledronic acid at any time
• •Previous treatment with teriparatide, alendronate or risedronate of more than 2 months in the last 24 months
• •Previous treatment with calcitonin within the previous year; previous treatment with an estrogen or selective estrogen modulator will not exclude a potential subject unless she has been taking it for \< 1 year (a woman who discontinued estrogen or a selective estrogen receptor within the previous year will also be excluded)
• •Other diseases known to affect bone, such as Paget's disease, Cushing's disease, hyperthyroidism, hyperparathyroidism, bone cancer and metastases to bone, and vitamin D deficiency
• •Medications known to affect bone, such as anticonvulsants, high dose glucocorticoids (20 mg/day or more \> 2 weeks within the previous 6 months)
• •Current alcohol use \> 3 drinks/day
• •Untreated or unstable cardiac, pulmonary, liver (SGOT \> 2X upper limit of normal) or renal disease (creatinine \> 1.2 mg/dL) or uncontrolled diabetes (hemoglobin A1C \> 8.0)
• •Prior radiation therapy to the skeleton
• •Cardiac pacemakers, ferromagnetic implants or brain aneurysm clips
• •Claustrophobia
• •Subjects whose initial MRI is of poor quality due to motion artifact will be asked to repeat the examination; if a repeat MRI is of poor quality due to motion artifact, the subject will be excluded from the study
• •Abnormalities of the which delay esophageal emptying such as stricture or achalasia
• •Inability to stand or sit upright for at least 30 minutes
• •Hypocalcemia
• •Uric acid level \>7.5ml/dl
• •Subjects with metallic objects in their bodies